AURO-LAMOTRIGINE 100 MG
LAMOTRIGINE : 100 MG · DIN 02381362 · AURO PHARMA INC
Health Canada status: MARKETED
What is AURO-LAMOTRIGINE?
AURO-LAMOTRIGINE 100 MG contains LAMOTRIGINE : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02381362, held by AURO PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 13-Jun-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AURO-LAMOTRIGINE used for?
Adjunctive therapy for epilepsy; monotherapy following AED withdrawal; adjunctive therapy for Lennox-Gastaut syndrome (adults and pediatrics).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02381362 |
|---|---|
| Brand name | AURO-LAMOTRIGINE |
| Generic / active ingredient | LAMOTRIGINE : 100 MG |
| Manufacturer | AURO PHARMA INC |
| Strength | 100 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N03AX09 LAMOTRIGINE |
| AHFS class | 28:12.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 13-Jun-2012 |
| Original market date | 2012-06-13 00:00:00 |
How is it administered?
Added to current therapy. Titration depends on concomitant AEDs (valproate vs. inducers). Maintenance: 100-200 mg/day (with VPA) to 300-500 mg/day (with inducers). Step-wise reduction recommended.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not specified in the provided text (Section 11 is listed in TOC but content is missing).
How is it supplied?
Not explicitly detailed in the provided text beyond tablet strengths (25, 100, 150 mg).
Contraindications
Hypersensitivity to lamotrigine or to any ingredient in the formulation or component of the container.
Warnings and precautions
Serious/fatal skin rashes (SJS/TEN); do not exceed titration rate; risk increased with valproic acid or history of AED rash; withdraw immediately if rash appears.
Is LAMOTRIGINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N03AX09 LAMOTRIGINE. 29 of 48 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-LAMOTRIGINE | 100 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02543729 |
| AG-LAMOTRIGINE | 150 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02543737 |
| AG-LAMOTRIGINE | 25 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02543710 |
| APO-LAMOTRIGINE | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 02245209 |
| APO-LAMOTRIGINE | 150 MG | TABLET | APOTEX INC | MARKETED | DIN 02245210 |
| APO-LAMOTRIGINE | 25 MG | TABLET | APOTEX INC | MARKETED | DIN 02245208 |
| AURO-LAMOTRIGINE | 150 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02381370 |
| AURO-LAMOTRIGINE | 25 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02381354 |
| JAMP LAMOTRIGINE | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02542749 |
| JAMP LAMOTRIGINE | 150 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02542757 |
Who else supplies LAMOTRIGINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LAMOTRIGINE appears in 882 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.